Cigna's revenue growth accelerated to 6.6% in Q2 2026, driven by Evernorth's pharmacy volumes, while the combined ratio remained stable near 96.3%. However, the loss ratio swung from 90.6% to 79.1% quarter-over-quarter, suggesting reserve releases may be maski...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 6.6% in Q2 2026, but the loss ratio swung from 90.6% to 79.1%, indicating reserve releases may be supporting earnings.
Cigna has consistently outperformed analyst expectations, with EPS surpassing forecasts and revenue growth exceeding consensus estimates. The company’s earnings quality is further supported by its disciplined cost control approach. This trend positions Cigna for continued profitability.
Cigna maintains resilient free cash flow, bolstered by modest leverage levels. The company’s disciplined cost control approach ensures cash generation remains strong. This financial strength provides flexibility for future growth initiatives.
Cigna’s Pharmacy Benefit Management (PBM) business has transitioned to a fee-based model, structurally de-risking the segment. The company has secured extended contracts with its largest PBM customers, enhancing long-term visibility. This shift supports sustainable revenue growth.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $7.78+2.4% vs $7.60 | $71.7B+2.2% vs $70.1B |
Q2 2026 Apr 30, 2026 | $7.79+2.5% vs $7.60 | $68.5B+3.3% vs $66.3B |
Q1 2026 Feb 5, 2026 | $8.08+2.5% vs $7.88 | $72.5B+3.1% vs $70.3B |
Q4 2025 Oct 30, 2025 | $7.83+2.5% vs $7.64 | $69.7B+3.2% vs $67.6B |
We believe that there is nothing more fundamental and reflective of economic health than the employment situation, and the latest data reflects an economy showing persistent growth. After July's disappointing payroll print, the August employment report rebounded strongly.
Building a two-site demonstration laboratory system together with the se miconductor - focused facility in Bengaluru, Hitachi High - Tech aims to strengthen the
CI is expanding AI across care coordination and specialty pharmacy as it seeks to manage elevated healthcare costs and improve access.
The Cigna Group's Vitality in America report finds people who volunteer feel healthier, more connected, and more resilient Research links employee volunteerism to higher job satisfaction, workplace pride, and engagement New tool measures the economic, health, and skills value generated through service BLOOMFIELD, Conn., Sept. 16, 2026 /PRNewswire/ -- New research from The Cigna Group (NYSE: CI) finds that volunteering is associated with better health, stronger workplace engagement, and greater connection to community.
Benchmark CI against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Cigna Corporation (CI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $273.74 | $72.41B | 12.35 | 11.26% | 2.17% | 14.33% | 2.21% | |
| $372.95 | $338.69B | 28.19 | 11.81% | 3.14% | 13.49% | — | |
| $402.43 | $87.27B | 16.02 | 12.62% | 2.47% | 11.2% | — | |
| $87.10 | $111.13B | 62.66 | 7.85% | 1.18% | 6.41% | — | |
| $371.93 | $44.65B | 37.80 | 10.06% | 0.88% | 6.89% | — | |
| $63.28 | $31.26B | -4.65 | 19.44% | -2.63% | -23.94% | — |
Cigna Corporation (CI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Cigna Corporation (CI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
May 13, 2026·SEC
Apr 30, 2026·SEC
Get notified when CI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cigna Corporation (CI) stock FAQ — growth, dividends, profitability & financials explained
Cigna Corporation (CI) grew revenue by 11.3% over the past year. This is steady growth.
Yes, Cigna Corporation (CI) is profitable, generating $6.42B in net income for fiscal year 2025 (2.2% net margin).
Yes, Cigna Corporation (CI) pays a dividend with a yield of 2.21%. This makes it attractive for income-focused investors.
Cigna Corporation (CI) has a return on equity (ROE) of 14.3%. This is reasonable for most industries.
Cigna Corporation (CI) has a combined ratio of 96.7%. A ratio below 100% indicates underwriting profitability.
